Emerging Biotech Firms Accelerate Drug Development with Veeva Basics Implementation

Accelerating Drug Development: The Impact of Veeva Basics on Emerging Biotech Companies

In a significant move to enhance operational efficiency and speed in drug development, over 175 emerging biotechnology firms have adopted Veeva Basics, as announced by Veeva Systems (NYSE: VEEV). This strategic initiative heralds a new era for these companies, enabling them to swiftly implement a robust technological infrastructure, essential for transitioning from the development phase to commercialization.

What is Veeva Basics?

Veeva Basics consists of pre-configured and pre-validated applications that support key operational areas, including clinical, regulatory, quality, medical, and commercial functionalities. The beauty of Veeva Basics lies in its ability to be deployed within weeks, allowing biotechnology firms to efficiently adapt their systems in line with their evolving business needs.

Bryan Ball, Chief Technology Operations Officer at Whitehawk Therapeutics, can attest to the transformative impact of Veeva's solutions, stating, "Our partnership with Veeva has allowed us to replace outdated paper processes with cutting-edge solutions without the need for an IT team or complex customizations. Veeva Basics has redefined our operations, significantly enhancing our processes in regulatory affairs and quality management. This shift has allowed us to speed up our operations and strengthen our compliance."

Internal vs. External Regulatory Strategies

One notable trend among the adopting firms is the internalization of their regulatory publishing strategies. Traditional approaches often relied on outsourcing, but Veeva’s modern solution, Veeva Submissions Publishing Basics, allows teams to manage compliance and regulatory submissions in-house. This shift not only improves the quality of control but also significantly reduces regulatory timelines.

Darryl Clarke, Global Head of Regulatory Operations at Structure Therapeutics, shared, "By internalizing our regulatory submissions through Veeva Basics, we have enhanced our quality control and dramatically shortened our regulatory timelines. We now benefit from modern applications with global support, capable of functioning swiftly and providing the flexibility needed for our growth."

Meeting Market Demands

As Jim Thai, Vice President of Veeva Basics, pointed out, emerging biotech companies are pivotal in driving innovation within the industry. They require technology that matches their rapid pace of development. Veeva Basics not only meets this demand but also empowers these companies to attain greater visibility and control throughout their regulatory lifecycle, building a solid foundation for their future.

Conclusion

With the capability to scale effortlessly alongside their business growth, Veeva Basics is becoming a preferred choice for emerging biotech firms seeking to bolster their drug development processes. For those interested in exploring the advantages of Veeva Basics, more information can be found at veevabasics.com. Additionally, the upcoming Veeva RD and Quality Summit, scheduled for October 20-21 in Boston, will provide further insights and networking opportunities exclusively for life sciences professionals.

About Veeva Systems

Veeva Systems stands out as a leading provider of cloud-based solutions tailored for the life sciences sector. Their commitment is rooted in innovation, excellence in product offerings, and ensuring customer success. With over 1,500 clients, ranging from top-tier global biopharmaceutical companies to innovative biotech startups, Veeva is dedicated to balancing the interests of all stakeholders involved, including customers, employees, shareholders, and the industries it serves.